Statins and pancreatic cancer risk: A nested case-control study

Cancer Causes and Control

Volumn 21, Issue 12, 2010, Pages 2093-2100

  Bradley, Marie C ^a   Hughes, Carmel M ^a   Cantwell, Marie M ^a   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

General practice research database; Pancreatic cancer; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; UNITED KINGDOM;

EID: 78751572934     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-010-9628-0     Document Type: Article

References (45)

1. A Jemal L Uegg E Ward 2004 Annual report to the Nation on the status of cancer 1975-2001 with a special feature regarding survival Cancer 101 3 27 10.1002/cncr.20288 15221985
2. Anderson KE, Potter J, Mack T (2006) Pancreatic cancer. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention. Oxford University Press, New York, pp 721-762
3. A Jemal R Siegel E Ward T Murray J XU M Thun 2007 Cancer statistics 2007 CA Cancer J Clin 57 43 66 10.3322/canjclin.57.1.43 17237035
4. JL Goldstein MS Brown 1990 Regulation of the mevalonate pathway Nature 343 425 430 1:CAS:528:DyaK3cXhtlCmtbw%3D 10.1038/343425a0 1967820
5. JA Stamm DL Ornstein 2005 The role of statins in cancer prevention and treatment Oncology (Williston Park) 19 739 750
6. L Vitek M Lenicek 2006 Cytoprotective and antiproliferative effects of HMG-CoA reductase inhibitors Current Enzyme Inhibition 2 261 280 1:CAS:528:DC%2BD28XnslClsrs%3D 10.2174/157340806777934775
7. K Keyomarsi L Sandoval V Band AB Pardee 1991 Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin Cancer Res 51 3602 3609 1:CAS:528:DyaK3MXksVWmsLY%3D 1711413
8. WW Wong J Dimitroulakos MD Minden LZ Penn 2002 HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis Leukemia 16 508 519 1:CAS:528:DC%2BD38XjvFGnurY%3D 10.1038/sj.leu.2402476 11960327
9. V Kaushal M Kohli P Mehta JL Mehta 2003 Potential anticancer effects of statins: fact or fiction? Endothelium 10 49 58 1:CAS:528:DC%2BD3sXitVCnu7o%3D 10.1080/10623320303358 12699077
10. S Sleijfer A Van Der Gaast AST Planting G Stoter J Verweij 2005 The potential of statins as part of anti-cancer treatment Eur J Cancer 41 516 522 1:CAS:528:DC%2BD2MXhvVChtr0%3D 10.1016/j.ejca.2004.12.009 15737555
11. L Blais A Desgagne J LeLorier 2000 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the risk of cancer: a nested case-control study Arch Intern Med 160 2363 2368 1:CAS:528:DC%2BD3cXmtlSlurg%3D 10.1001/archinte.160.15. 2363 10927735
12. S Friis AH Poulsen SP Johnsen JK McLaughlin JP Fryzek SO Dalton HT Sorensen JH Olsen 2005 Cancer risk among statin users: a population-based cohort study Int J Cancer 114 643 647 1:CAS:528:DC%2BD2MXisVWisLs%3D 10.1002/ijc.20758 15578694
13. MR Graaf AB Beiderbeck AC Egberts DJ Richel HJ Guchelaar 2004 The risk of cancer in users of statins J Clin Oncol 22 2388 2394 1:CAS:528: DC%2BD2cXpsVWlu78%3D 10.1200/JCO.2004.02.027 15197200
14. JA Cauley JM Zmuda LY Lui TA Hillier RB Ness KL Stone SR Cummings DC Bauer 2003 Lipid-lowering drug use and breast cancer in older women: a prospective study J Womens Health (Larchmt) 12 749 756 10.1089/ 154099903322447710
15. J Shannon S Tewoderos M Garzotto TM Beer R Derenick A Palma PE Farris 2005 Statins and prostate cancer risk: a case-control study Am J Epidemiol 162 318 325 10.1093/aje/kwi203 16014776
16. V Khurana HR Bejjanki G Caldito MW Owens 2007 Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans Chest 131 1282 1288 10.1378/chest.06-0931 17494779
17. JN Poynter SB Gruber PD Higgins R Almog JD Bonner HS Rennert M Low JK Greenson G Rennert 2005 Statins and the risk of colorectal cancer N Engl J Med 352 2184 2192 1:CAS:528:DC%2BD2MXksFOmurY%3D 10.1056/NEJMoa043792 15917383
18. KM Dale CI Coleman NN Henyan J Kluger CM White 2006 Statins and cancer risk: a meta-analysis JAMA 295 74 80 1:CAS:528:DC%2BD28XhtlOgsQ%3D%3D 10.1001/jama.295.1.74 16391219
19. S Bonovas K Filioussi N Tsavaris NM Sitaras 2006 Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials J Clin Oncol 24 4808 4817 1:CAS:528:DC%2BD28Xht1eiu73M 10.1200/JCO.2006.06.3560 17001070
20. S Bonovas K Filioussi NM Sitaras 2008 Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies Am J Gastroenterol 103 2646 2651 1:CAS:528:DC%2BD1cXhtlaksLnI 10.1111/j.1572-0241.2008.02051.x 18684187
21. V Khurana A Sheth G Caldito JS Barkin 2007 Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans Pancreas 34 260 265 1:CAS:528:DC%2BD2sXjs1Glsbg%3D 10.1097/MPA.0b013e318030e963 17312467
22. JA Kaye H Jick 2004 Statin use and cancer risk in the general practice research database Br J Cancer 90 635 637 1:CAS:528:DC%2BD2cXoslKjtw%3D%3D 10.1038/sj.bjc.6601566 14760377
23. T Walley P Folino-Gallo P Stephens E Van Ganse 2005 Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003 Br J Clin Pharmacol 60 543 551 1:STN:280:DC%2BD2MrlvFKqtQ%3D%3D 10.1111/j.1365-2125.2005.02478.x 16236045
24. T Walley P Folino-Gallo U Schwabe E Van Ganse 2004 Variations and increase in use of statins across Europe: data from administrative databases BMJ 328 385 386 10.1136/bmj.328.7436.385 14962875
25. J Hollowell 1997 The general practice research database: quality of morbidity data Popul Trends 87 36 40 9134574
26. LA Garcia Rodriguez S Perez Gutthann 1998 Use of the UK general practice research database for pharmacoepidemiology Br J Clin Pharmacol 45 419 425 1:STN:280:DyaK1czgsFOltw%3D%3D 10.1046/j.1365-2125.1998.00701.x 9643612
27. H Jick SS Jick LE Derby 1991 Validation of information recorded on general practitioner based computerised data resource in the United Kingdom BMJ 302 766 768 1:STN:280:DyaK3M3hsFentQ%3D%3D 10.1136/bmj.302.6779.766 2021768
28. H Jick BZ Terris LE Derby SS Jick 1992 Further validation of information recorded on a general practicioner based computerised data resource in the United Kingdom Pharmacoepidemiol Drug Saf 1 347 349 10.1002/pds.2630010607
29. T Van Staa L Abenhaim 1994 The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycaemia and other conditions Pharmacoepidemiol Drug Saf 3 15 21 10.1002/pds.2630030106
30. H Kinnear A Gavin D Mole L Ranaghan 2005 Cancer services audit 2001, pancreas N Ireland Cancer Registry 1 30
31. British Medical Association and Royal Pharmaceutical Society of Great Britain (2008) British National formulary 55:140-143
32. World Health Organisation collaborating group for Drug Statistics Methodology. Purpose of the ATC/DDD system. [internet] [cited 2010 Jan 20, updated 2009 Oct 29] Available from http://www.whocc.no/atc-ddd-index/
33. YX Yang S Hennessy K Propert WT Hwang A Sedarat JD Lewis 2007 Chronic proton pump inhibitor therapy and the risk of colorectal cancer Gastroenterology 133 748 754 1:CAS:528:DC%2BD2sXhtFarsrbJ 10.1053/j.gastro.2007.06.022 17678926
34. World Health Organisation Working Group. Global Database on Body Mass Index: BMI Classification [internet] 2006[Cited 2009 Dec 12, Updated 2010 Mar 29]. Available from http://apps.who.int/bmi/index.jsp?introPage=intro-3.html
35. JC LaRosa SM Grundy DD Waters C Shear P Barter JC Fruchart AM Gotto H Greten JJ Kastelein J Shepherd NK Wenger 2005 Treating to new targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425 1435 1:CAS:528: DC%2BD2MXjtVWltrw%3D 10.1056/NEJMoa050461 15755765
36. The Post Coronary Bypass Graft Trial Investigators 1997 The effect of aggressive lowering of low density lipoprotein, cholesterol levels and low dose anti-coagulation on obstructive changes in sapherous-vein coronary-artery bypass grafts N Engl J Med 336 153 162 10.1056/NEJM199701163360301
37. SE Nissen EM Tuzcu P Schoenhagen BG Brown P Ganz RA Vogel T Crowe G Howard CJ Cooper B Brodie CL Grines AN DeMaria, et al. 2004 Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 1071 1080 1:CAS:528:DC%2BD2cXhvFent78%3D 10.1001/jama.291.9.1071 14996776
38. M Clearfield JR Downs S Weis EJ Whitney W Kruyer DR Shapiro EA Stein A Langendorfer PA Beere AM Gotto 2001 Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women J Womens Health Gend Based Med 10 971 981 1:STN:280:DC%2BD38%2FmtlSjuw%3D%3D 10.1089/152460901317193549 11788107
39. TE Strandberg K Pyorala TJ Cook L Wilhelmsen O Faergeman G Thorgeirsson TR Pedersen J Kjekshus 2004 Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) Lancet 364 771 777 1:CAS:528:DC%2BD2cXntVOjt7c%3D 10.1016/S0140-6736(04)16936-5 15337403
40. PW Serruys P de Feyter C Macaya N Kokott J Puel M Vrolix A Branzi MC Bertolami G Jackson B Strauss B Meier 2002 Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 3215 3222 1:CAS:528:DC%2BD38XkvVOjtr8%3D 10.1001/jama.287.24.3215 12076217
41. H Gbelcova M Lenicek J Zelenka Z Knejzlik G Dvorakova M Zadinova P Pouckova M Kudla P Balaz T Ruml L Vitek 2008 Differences in antitumor effects of various statins on human pancreatic cancer Int J Cancer 122 1214 1221 1:CAS:528:DC%2BD1cXit1yhsrY%3D 10.1002/ijc.23242 18027870
42. Dorais M, Tamaz R, Rakel A, Lelorrier J, Panzini B (2007) Statins, nsaids and pancreatic cancer. Poster presented at the 23rd International conference in Pharmacoepidemiology 2007 19-22 Aug, Quebec City, Canada. Available in Pharmacoepidemiol Drug Saf 16 (Suppl 2): s93-Abstract 195
43. PF Coogan L Rosenberg BL Strom 2007 Statin use and the risk of 10 cancers Epidemiology 18 213 219 10.1097/01.ede.0000254694.03027.a1 17235211
44. MR Graaf AB Beiderbeck ACG Egberts DJ Richel H Guchelaar 2004 The risk of cancer in users of statins J Clin Oncol 22 2388 2394 1:CAS:528: DC%2BD2cXpsVWlu78%3D 10.1200/JCO.2004.02.027 15197200
45. JH Olsen C Johansen HT Sorensen JK McLaughlin L Mellemkjaer FH Steffensen JF Fraumeni Jr 1999 Lipid-lowering medication and risk of cancer J Clin Epidemiol 52 167 169 1:STN:280:DyaK1M3hsFynsA%3D%3D 10.1016/S0895-4356(98)00147- 4 10201659